Literature DB >> 9761250

Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC.

E Schütz1, D Svinarov, M Shipkova, P D Niedmann, V W Armstrong, E Wieland, M Oellerich.   

Abstract

Assays with different specificity are used for cyclosporin monitoring in clinical transplantation. A recent survey of 35 centers showed that 86% used immunoassays for cyclosporin A (CsA). In consensus documents the following performance criteria were recommended: (a) imprecision < or = 10% at 50 microg/L and < or = 5% at 300 microg/L; and (b) comparison with the reference method (HPLC) should yield a slope of 0.9-1.1, an intercept of -15 to 15 microg/L, and S(y/x) < or = 15 microg/L. The newly developed CsA assays for the AxSYM (Abbott) and the CEDIA (Boehringer Mannheim) as well as the Emit assay (Behring Diagnostica) were evaluated. Results from samples of heart, kidney, and liver recipients (100 specimens each) were compared with a validated HPLC-ultraviolet detection method. Between-series imprecision (CV) with commercial controls was 5.8% and 1.7% for AxSYM (70 and 300 microg/L), 11% and 5.5% for CEDIA (90 and 200 microg/L), and 8.1% and 4.5% for Emit (63 and 172 microg/L). In the presence of 300 microg/L parent CsA, cross-reactivities were (for AxSYM, CEDIA, and Emit, respectively) 7%, 4%, and none for AM1 (1 mg/L) and 12.6%, 25%, and 6% for AM9 (0.5 mg/L). Comparison with HPLC showed in heart and kidney recipients an average overestimation with the Emit and the CEDIA of approximately 22%, with overestimation in the AxSYM of 32%. In liver recipients, the most challenging patient group, the CEDIA and the AxSYM showed a mean overestimation of 43% and 47%, respectively, and the Emit differed by 31% compared with HPLC. None of the immunoassays fully satisfied the performance criteria recommended in the consensus documents. In terms of specificity, Emit ranks before CEDIA, which ranks before AxSYM. Regarding imprecision, the ranking is AxSYM < Emit < CEDIA. These limitations must be considered when using these assays for therapeutic drug monitoring of CsA in clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761250

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

2.  Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT 2000 cyclosporine specific assay with the COBAS MIRA-plus analyzer.

Authors:  S Kimura; S Iyama; Y Yamaguchi; Y Kanakura
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

3.  Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay.

Authors:  Pierre Wallemacq; Gregory T Maine; Keith Berg; Thomas Rosiere; Pierre Marquet; Giuseppe Aimo; Giulio Mengozzi; Julianna Young; Kurt Wonigeit; Robert Kretschmer; Bendicht Wermuth; Rainer W Schmid
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

Review 4.  Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

Authors:  C J Dunn; A J Wagstaff; C M Perry; G L Plosker; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Cyclosporin therapeutic drug monitoring--an established service revisited.

Authors:  Raymond G Morris
Journal:  Clin Biochem Rev       Date:  2003-05

6.  Standardization of a dilution method for cyclosporin (C2) estimation in renal transplant patients.

Authors:  G Kusumanjali; Chinnapu G Reddy; A S Kanagasabapathy; Pragna Rao
Journal:  Indian J Clin Biochem       Date:  2005-07

7.  A review on therapeutic drug monitoring of immunosuppressant drugs.

Authors:  Niloufar Mohammadpour; Sepideh Elyasi; Naser Vahdati; Amir Hooshang Mohammadpour; Jamal Shamsara
Journal:  Iran J Basic Med Sci       Date:  2011-11       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.